About this trial
The Alzheimer's disease or related disorders (ADRD) are among the most disabling diseases because of their main features such as cognitive impairment, loss of functional autonomy and behavioural disorders. In absence of current curative treatment, the identification of the predictive risk factors of progression of the disease, evaluated through its main symptoms, represents a major stake of public health. The Investigators aim at developing a regional database, which includes the patient medical records on a prospective basis, in collaboration with the medical and administrative staff and with the University hospital computer science departments.
The main objective is to study the predictive factors associated with change in functional autonomy level, measured every 6 to 12 months in centres across Region Auvergne Rhone-Alpes in France.
The real-life study population will consist in about 5400 patients with ADRD. The inclusion period will be of 3 years, the length of follow-up of each patient will be of 10 years max for a total study length of 13 years.
Eligibility criteria
Qualifiers
Patients aged 18 years and older, undergoing a medical visit in a memory center or neuro-cognition service
Patients living at home or in housing
Patients with memory impairment, at all stage of the disease
Disqualifiers
Patients in institution
Patients under legal protection
Patients with a hearing or visual impairment, which prevents carrying out examinations
Trial design
Treatments tested in this trial
- no intervention